Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494461 | 1.00 | BACE1 (0.37) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL3494462 | 1.00 | BACE1 (0.37) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL2819818 | 0.88 | KDM4E (0.40) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL2819817 | 0.88 | KDM4E (0.40) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL3891195 | 0.87 | CYP3A4 (0.36) | BACE1 | |
| SCHEMBL3891190 | 0.87 | CYP3A4 (0.36) | BACE1 | |
| SCHEMBL756120 | 0.87 | PDK1 (0.38) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL8247533 | 0.84 | BACE1 (0.40) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL758064 | 0.84 | BACE1 (0.40) | BACE1PDK1PDK2PDK3PDK4 | |
| SCHEMBL14640804 | 0.83 | BACE1 (0.37) | BACE1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2091328-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
| WO-2008054698-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | BACE1 1/4885PDK1 1758/4885PDK2 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.